MemorialCare Heart & Vascular Institute Completes First Successful TriClip Procedure for Tricuspid Valve Repair
The FDA-approved TriClip is a small clipping device designed to clip two or more of the leaflets of the tricuspid, offering a minimally invasive treatment option to patients who have tricuspid regurgitation (TR) – a condition where the tricuspid valve does not close completely when the right ventricle contracts. This device – implanted via a catheter inserted in the vein of the leg – helps reduce tricuspid regurgitation and promotes an immediate improvement in blood flow and allows patients to benefit from a less traumatic procedure and a faster recovery.
This advanced technology marks a new era for treating tricuspid valve disease since prior to its introduction, patients could only receive a device better suited for the mitral valve (MitraClip® device). The TriClip device was specifically made for the tricuspid valve. In a large clinical trial, the device was shown to reduce symptoms and hospitalization for heart failure for patients at high-risk for open-heart surgery.
"This new procedure represents a significant advancement in our ability to treat high-risk patients with tricuspid valve heart disease," says Dr. Shavelle, who led the landmark procedure. "Historically there wasn't much we could do for those who still had symptoms after tricuspid regurgitation treatment and who were at high-risk for open heart surgery. This device gives patients access to improved quality of life."
This procedure was performed by a highly skilled, diverse team of cardiologists, cardiac surgeons, cardiac anesthesiologists and advanced imaging specialists from the MemorialCare Heart & Vascular Institute at Long Beach Medical Center. Implantation of the TriClip with the TriClip G4 System is as effective as open-heart surgery, helping patients return to their daily lives in one to two days.
"The patient recovered in the hospital for about two days, and he was able to return to his daily life the following day," says Dr. Shavelle. "It's amazing to see the positive impact this device has on our patients, allowing them to return to their daily lives with improved heart function and overall well-being."
The patient who received this procedure, Anthony Williams, reported being fatigued constantly with excessive swelling of the legs (edema) before the procedure. Today, he is more energetic than ever and ready to take on each day.
MemorialCare Heart & Vascular Institute at Long Beach Medical Center is the first institute in the region to use this device and continues to lead in cardiovascular innovations, bringing patients with the latest technology advancements. As one of the most high performing hospitals according to U.S. News, MemorialCare Long Beach Medical Center is a six-time five-star recipient recognized for its excellence in cardiac care by Healthgrades, and has recently received the American Heart Association's Get With The Guidelines® Heart Failure Gold Plus Quality Achievement Award, as well as the American Heart Association/American Stroke Association's Get With The Guidelines® Stroke Gold Plus Quality Achievement Award. With these achievements and offering a comprehensive range of services for patients with cardiac disorders, including rehabilitation programs, Long Beach Medical Center is a community hospital dedicated in providing expert and compassionate care on par with those found in academic settings.
About MemorialCare Long Beach Medical Center:
MemorialCare Long Beach Medical Center is a member of MemorialCare, a not-for-profit, integrated healthcare system. Long Beach Medical Center has been providing the community with compassionate, quality health care for more than 100 years. At the forefront of specialized care, research, and education, Long Beach Medical Center uses the most advanced healthcare technologies, including pioneering surgical systems like – ExactechGPS® and ExcelsiusGPS®. Recognized among the top 3% of all California acute care hospitals, Long Beach Medical Center is recognized as "Best Hospital" for OBGYN and Orthopedics and ranked regionally in the Los Angeles Metro Area by U.S. News & World Report and earned Magnet® recognition for nursing excellence. With premier centers dedicated to cancer, heart, rehabilitation, orthopedics, neurosciences, and trauma, physicians and surrounding hospitals continually refer to its accredited programs. For more information, visit memorialcare.org/LongBeach.
View original content to download multimedia:https://www.prnewswire.com/news-releases/memorialcare-heart--vascular-institute-completes-first-successful-triclip-procedure-for-tricuspid-valve-repair-302473472.html
SOURCE MemorialCare Long Beach Medical Center
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Lead-Free Piezoelectric Ceramics Market to Grow 12.3% Annually Through 2030
"Driven by Rising Environmental Regulations and Breakthrough R&D, Lead-Free Piezoelectric Ceramics Emerge as a Key Enabler of Sustainable Electronics Innovation" BOSTON, Aug. 20, 2025 /PRNewswire/ -- According to the latest study from BCC Research, the "Lead-Free Piezoelectric Ceramics: Technologies and Global Opportunities" is projected to grow from $307.3 million in 2025 to $549.8 million by the end of 2030, at a compound annual growth rate (CAGR) of 12.3% from 2025 through 2030. This report presents a comprehensive analysis of the global market for lead-free piezoelectric ceramics, offering qualitative and quantitative insights. The market is segmented by material, including potassium sodium niobate (KNN), bismuth sodium titanate (BNT), barium titanate (BT), and others. It is also categorized by configuration, such as monolith, multilayer, and thin films, and by end users, including consumer electronics and optoelectronics, transportation, industrial equipment, medical, and others. Regional analysis covers Asia-Pacific (China, Japan, South Korea, and the rest of APAC), Europe (Germany, France, Italy, and the rest of Europe), North America (U.S., Canada, and Mexico), and the Rest of the World (RoW). RoW includes South America, and the Middle East, and Africa. This report is especially relevant now due to growing global concerns over the health and environmental risks associated with lead, a key component in traditional PZT piezoelectric materials. As awareness of these risks increases, industries and researchers are actively seeking eco-friendly alternatives. Additionally, stricter regulations under frameworks like REACH and ROHS are accelerating the shift toward lead-free technologies. These regulatory pressures, particularly in the European Union, are expected to gradually phase out lead-based materials in specific applications, making the development and adoption of lead-free piezoelectric ceramics a timely and critical focus. The factors driving the market's growth include: Adverse Health and Ecological Impacts of Lead-Based Piezoelectric Materials: Due to lead toxicity, lead-based ceramics pose serious health risks and environmental hazards. Exposure can lead to neurological and developmental issues, while improper disposal contaminates ecosystems. These dangers are pushing industries to adopt safer, lead-free alternatives. Favorable Regulatory Environment: Global regulations like the EU's RoHS and WEEE directives restrict the use of hazardous substances, including lead, in electronics. These policies encourage manufacturers to shift toward environmentally friendly materials, creating a supportive market for lead-free piezoelectric ceramics. Increasing Applications for Lead-Free Piezoelectric Ceramics: Advances in material science have expanded the use of lead-free ceramics across sectors such as consumer electronics, healthcare, automotive, and industrial automation. Their growing versatility and safety make these materials a preferred choice for modern applications. Request a sample copy of the global market for lead-free piezoelectric ceramics report. Report Synopsis Report Metric Details Base year considered 2024 Forecast period considered 2025-2030 Base year market size $279.0 million Market size forecast $549.8 million Growth rate CAGR of 12.3% from 2025 to 2030 Segments covered Material, Configuration, End User, and Region Regions covered North America, Europe, Asia-Pacific, and the Rest of the World (RoW) Countries covered The U.S., Canada, Mexico, Germany, France, Italy, Rest of Europe, China, Japan, South Korea, Rest of Asia-Pacific, South America, and the Middle East and Africa Market drivers • Adverse health and ecological impacts of lead-based piezoelectric materials. • Favorable regulatory environment. • Increasing applications for lead-free piezoelectric ceramics. Interesting facts: At present, the production of lead-free piezoelectric ceramics is more complex, expensive, and energy-intensive than PZT because of the small quantities involved. Lead-free piezoelectric ceramics producers also face certain challenges, including higher cost of raw materials, more complex processing, delicate and irreproducible synthesis, and physical limitations of the lead-free composition. However, they are continuously expanding their production and development capabilities to cater to growing demand and customer requirements. In wearable applications, self-powered biocompatible electronic devices that monitor critical physiological signals of the human body are in high demand. Lead-free piezoelectric ceramics are non-toxic and can be effectively utilized as they are biocompatible and have high sensing capabilities. Emerging startups: Ionix AT: Ionix develops a wide range of proprietary high-performance piezoelectric materials that can function in extreme environments. It supplies sensors, transducers, and actuators that address market needs for high-performance applications. The report addresses the following questions: 1. What are the projected market size and growth rate? The estimated market size of the lead-free piezoelectric ceramics market is $549.8 million by the end of 2030. The CAGR is 12.3%. 2. Which factors are driving the growth of the market? Key market drivers include: Adverse health and ecological impact of lead-based piezoelectric materials. Favorable regulatory environment. Increasing applications of lead-free piezoelectric ceramics. 3. What are the challenges and opportunities of the market? Challenges include- Raw material extraction may lead to environmental risks. Performance constraints. - Opportunities include- Development of nano-piezoelectric ceramics. Applications within wearable technology. 4. Which market segments are covered in the report? Material, configuration, end-user, and region. 5. Which material will be dominant through 2030? The potassium sodium niobate segment will continue to dominate the market through 2030. 6. Which region has the largest market share? Asia-Pacific dominates the global market for lead-free piezoelectric ceramics. China continues to drive the demand for lead-free piezoelectric ceramics, led by its robust manufacturing industry, mainly in automotive, electronics, and medical. Market leaders include: CERAMTEC GMBH CTS CORP. FUJI CERAMICS CORP. HONDA ELECTRONICS CO. LTD. IONIX AT KEMET CORP. KYOCERA CORP. NITERRA CO. LTD. NINGBO FBELE ELECTRONICS CO. LTD. PI CERAMIC GMBH PZT ELECTRONIC CERAMIC CO., LTD. SEIKO EPSON CORP. SUMITOMO CHEMICAL CO., LTD. TANIOBIS ZIBO YUHAI ELECTRONIC CERAMIC CO., LTD. Related reports: Global Markets for Automotive Sensor Technologies: The report analyzes the global automotive sensor market, focusing on sensor types, applications, vehicle categories, propulsion technologies, sales channels, and regional trends. It excludes two-wheelers and agricultural/industrial vehicles. Key segments include passenger and commercial vehicles, ICE and alternative fuel technologies, and OEM vs. aftermarket sales. The study highlights sensor deployment in areas like powertrain, safety, and autonomous systems. Purchase a copy of the report direct from BCC Research. For further information on any of these reports or to make a purchase, contact info@ About BCC Research BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype. Contact UsCorporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USAEmail: info@ +1 781-489-7301For media inquiries, email press@ or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. Logo: View original content to download multimedia: SOURCE BCC Research LLC Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
26 minutes ago
- Business Wire
Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse
NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it has submitted the final module of its Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for Evolysse ™ Sculpt, an injectable hyaluronic acid (HA) gel product designed to restore mid-face volume. 'This submission represents an important milestone in expanding our Evolysse ™ collection of injectable HA gels,' said Dr. Rui Avelar, MD, Chief Medical Officer and Head of R&D. 'Sculpt is our most structured product, manufactured using a novel technology and designed to address mid-face volume loss, a high-value segment in facial aesthetics.' Evolus anticipates that the FDA's review will follow the standard PMA process, with approval expected in the second half of 2026. The submission underscores Evolus' commitment to bringing its collection of injectable hyaluronic acid gel products to market and its readiness to meet rigorous regulatory requirements. In support of the PMA application, a U.S. pivotal study which evaluated the safety and effectiveness of the product in a multicenter, double-blinded, controlled, non-inferiority designed trial was conducted. Patients were followed for 24 months from initial treatment. A total of 304 patients were enrolled and randomized to receive Evolysse ™ Sculpt or Restylane ® -Lyft. The Evolysse ™ Sculpt injectable HA gel product is expected to be the flagship brand in the Evolysse ™ collection. Designed by Symatese using innovative Cold-X ™ technology, which helps preserve the natural structure of the HA molecule for long-lasting, natural-looking results, Sculpt will enter the highest value segment for today's dermal filler market and be among the few products currently indicated for the mid-face area. About Evolus, Inc. Evolus (NASDAQ: EOLS) is a global performance beauty company redefining the aesthetic injectable market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global leader in aesthetics anchored by our flagship products: Jeuveau ® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics, and Evolysse ™, a collection of unique injectable hyaluronic acid (HA) gels. Visit us at and follow us on LinkedIn, X, Instagram or Facebook. Forward-Looking Statements This press release contains forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, including statements about future events, our business, financial condition, results of operations and prospects, our industry and the regulatory environment in which we operate. Any statements contained herein that are not statements of historical or current facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'will,' 'would' or the negative of those terms, or other comparable terms intended to identify statements about the future. The company's forward-looking statements include, but are not limited to, statements related to anticipated product launches and the timing of regulatory submissions and approvals. The forward-looking statements included herein are based on our current expectations, assumptions, estimates and projections, which we believe to be reasonable, and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements. These risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond our control, include, but are not limited to, uncertainties associated with our ability to comply with the terms and conditions in the Medytox Settlement Agreements, our ability to fund our future operations or obtain financing to fund our operations, unfavorable global economic conditions and the impact on consumer discretionary spending, uncertainties related to customer and consumer adoption of Jeuveau ® and Evolysse ™, the efficiency and operability of our digital platform, competition and market dynamics, our ability to successfully launch and commercialize our products in new markets, including the Evolysse ™ dermal filler product line in the U.S., our ability to maintain regulatory approvals of Jeuveau ® or obtain regulatory approvals for new product candidates or indications, our reliance on Symatese to achieve regulatory approval for the Evolysse ™ dermal filler product line in the U.S., and other risks described in our filings with the Securities and Exchange Commission, including in the section entitled 'Risk Factors' in our Annual Report on Form 10-K and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 filed with the Securities and Exchange Commission on August 5, 2025. These filings can be accessed online at Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information, changed circumstances or unanticipated events. If we do update or revise one or more of these statements, investors and others should not conclude that we will make additional updates or corrections. Jeuveau ® and Nuceiva ®, are registered trademarks and Evolysse ™ is a trademark of Evolus, Inc. Hi-Pure ™ is a trademark of Daewoong Pharmaceutical Co, Ltd. Cold-X ™ and Estyme ® are trademarks of Symatese Group and Symatese Aesthetics S.A.S. Restylane ® is a trademark of Galderma S.A.
Business Wire
26 minutes ago
- Business Wire
Nucleus RadioPharma Appoints Former FDA Commissioner Dr. Stephen Hahn as CEO to Scale Patient Access to Radiopharmaceutical Therapies
ROCHESTER, Minn.--(BUSINESS WIRE)-- Nucleus RadioPharma, a next-generation contract development and manufacturing organization (CDMO) specializing in radiopharmaceuticals, today announced the appointment of Dr. Stephen M. Hahn as chief executive officer. Hahn's leadership signals Nucleus RadioPharma's urgency in scaling the infrastructure necessary to make minimally invasive, targeted cancer therapies accessible to patients around the world. Hahn joins Nucleus RadioPharma after serving as CEO-partner of Flagship Pioneering and CEO of Harbinger Health since 2021. He served as the 24th U.S. Food and Drug Administration (FDA) commissioner from 2019 to 2021, overseeing both COVID and non-COVID regulatory affairs. Before joining the FDA, he was the chief medical executive at MD Anderson Cancer Center in Houston. The combination of regulatory, clinical and operational knowledge gives him deep insight into how therapies move from clinic to patient. Radiopharmaceuticals represent one of the most promising frontiers in oncology, offering treatments that are less toxic, less invasive and far more precise in targeting cancer cells. When patients receive these therapies, outcomes improve and quality of life is preserved. However, widespread access to radiopharmaceuticals remains extremely limited, not due to scientific barriers, but logistical ones. Three interdependent issues drive these supply chain challenges: a fragile and insufficient supply of key isotopes, limited GMP-compliant infrastructure capable of handling a range of medical isotopes and an underdeveloped operational capacity to manage radioactive drugs. 'Radiopharmaceuticals are the next frontier of precision oncology care,' said Hahn. 'But without the infrastructure to deliver these treatments, their impact is fundamentally limited. At Nucleus RadioPharma, we have an extraordinary team that is committed to breaking those barriers. Together, we will scale the systems and infrastructure needed to make these lifesaving therapies available to all who need them.' Under Hahn's leadership, Nucleus RadioPharma is uniquely positioned to tackle these issues, take radiopharmaceuticals to new levels of precision and efficacy and make minimally invasive therapies the new standard for cancer treatment. 'Steve's experience as both a physician treating patients and as a leader at the FDA brings an unparalleled perspective to Nucleus as the company works to build the infrastructure needed to accelerate the widespread availability of radiopharmaceuticals,' said Justin Butler, partner at Eclipse and Nucleus board member. 'His new role is a major indicator to the oncology community that radiopharmaceuticals are the future of precision cancer treatment, and that Nucleus is poised to lead the next era.' Founded in 2022 through a collaboration between Eclipse and Mayo Clinic, Nucleus has raised $72 million in funding to date, including participation from AstraZeneca. The company is building a network of advanced facilities, starting in Mesa, Arizona, and Spring House, Pennsylvania, that integrate research, development and commercial-scale production under one roof, enabling faster, more reliable distribution to clinical trial sites and treatment centers. 'With one of the largest cancer theranostics practices in the world, we have a responsibility to drive continual innovation and develop new targeted diagnostic and therapeutic radioisotopes for our patients,' said Dr. Cheryl Willman, Stephen and Barbara Slaggie executive director for Mayo Clinic Cancer Programs and Mayo Clinic Comprehensive Cancer Center. 'With Steve's exemplary leadership skills and expertise as a cancer physician and scientist, our future could not be brighter.' In his first year as CEO, Hahn will focus on completing the company's GMP readiness at its Rochester, Minnesota, facility, expanding R&D capabilities, launching Nucleus' data platform and forging strategic partnerships. Over the next five years, the company aims to dramatically increase manufacturing capacity and advance initiatives that improve patient access worldwide. For more information on Nucleus RadioPharma, see here. Nucleus RadioPharma is an innovative CDMO dedicated to the development and manufacturing of targeted radiotherapies. With an emphasis on innovation and quality, Nucleus provides an array of services, from formulation and analytical development to regulatory documentation and drug product manufacturing. Its technology platforms are at the forefront of radiopharmaceutical research, designed to advance new therapies through clinical trials to commercialization. Learn more at
